MP 13 Ventures, LLC

CIK 1629186 · last filed 2026-04-02

MP 13 Ventures, LLC is a corporate insider who has filed 8 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing shows the insider converted $125.0M of IBRX on Apr 2, 2026. Across all open-market trades the lifetime net is −$2.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $623.2M across reported positions. The firm reports its address in El Segundo, CA. 29 SEC filings were submitted jointly with Cambridge Equities, LP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$623.17M

Companies

4

Total Filings

8

Lifetime Open-Market Net

-$2.94M

Filer Profile

Reported Address

450 DULEY ROAD
EL SEGUNDO, CA 90245

Phone

(310) 836-6400

State of Incorporation

Related Filers

Cambridge Equities, LP — 29 joint filings, latest 2026-04-02

PATRICK SOON-SHIONG — 28 joint filings, latest 2026-04-02

Sorrento Therapeutics, Inc. — 9 joint filings, latest 2016-07-11

CALIFORNIA CAPITAL EQUITY, LLC — 8 joint filings, latest 2026-04-02

Nant Capital, LLC — 7 joint filings, latest 2026-04-02

Chan Soon-Shiong Family Foundation — 6 joint filings, latest 2016-07-11

NantWorks, LLC — 1 joint filings, latest 2021-04-15

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
IBRX	10%+ Owner	77,315,845	$8.06	$623.17M	$0	2	2026-04-02
ImmunityBio, Inc. (NK) Delisted	10%+ Owner	41,165,814	—	—	$0	1	2018-07-13
NantHealth, Inc. (NH) Delisted	10%+ Owner	—	$1.35	—	$0	1	2016-12-23
Sorrento Therapeutics, Inc. (SRNE) Delisted	10%+ Owner	7,888,399	$0.00	$3.9K	-$2.94M	4	2016-06-17

Recent Filings

8 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-04-02	IBRX	Conv (C)	+23,032,980	$125.00M	EDGAR
2024-12-12	IBRX	Mixed	+585,926,300	$1.16B	EDGAR
2018-07-13	ImmunityBio, Inc. (NK) Delisted	Exer (M)	+27,771	$45.0K	EDGAR
2016-12-23	NantHealth, Inc. (NH) Delisted	Buy (P)	—	$0	EDGAR
2016-06-17	Sorrento Therapeutics, Inc. (SRNE) Delisted	Sell (S)	−79,344	-$465.9K	EDGAR
2016-03-08	Sorrento Therapeutics, Inc. (SRNE) Delisted	Sell (S)	−400,000	-$2.48M	EDGAR
2015-12-10	Sorrento Therapeutics, Inc. (SRNE) Delisted	Grant (A)	+119,292	$945.9K	EDGAR
2015-12-09	Sorrento Therapeutics, Inc. (SRNE) Delisted	Grant (A)	+342,000	$2.70M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.